Cargando…

Effect of L. reuteri on bowel movements in children aged 6 months to 4 years: A double-blind randomized controlled trial

BACKGROUND: Chronic constipation is common in children and often requires prolonged laxative treatment. Preliminary studies suggest that the probiotic Limosilactobacillus reuteri (L. reuteri) may be useful in treating constipation in children, but these preliminary results need to be replicated. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Camille, Kalach, Nicolas, Degas, Vanessa, Jeridi, Yasmine, Bertrand, Valérie, Bellaiche, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643683/
https://www.ncbi.nlm.nih.gov/pubmed/36389355
http://dx.doi.org/10.3389/fped.2022.997104
_version_ 1784826569624125440
author Jung, Camille
Kalach, Nicolas
Degas, Vanessa
Jeridi, Yasmine
Bertrand, Valérie
Bellaiche, Marc
author_facet Jung, Camille
Kalach, Nicolas
Degas, Vanessa
Jeridi, Yasmine
Bertrand, Valérie
Bellaiche, Marc
author_sort Jung, Camille
collection PubMed
description BACKGROUND: Chronic constipation is common in children and often requires prolonged laxative treatment. Preliminary studies suggest that the probiotic Limosilactobacillus reuteri (L. reuteri) may be useful in treating constipation in children, but these preliminary results need to be replicated. The objective of this study was to assess the efficacy of L. reuteri in infants and young children with chronic functional constipation. METHODS: A prospective double-blind randomized placebo-controlled trial was conducted in 5 pediatric departments in France between June 2017 and June 2021. In all, 49 patients—ages 6 months to 4 years, and suffering from chronic constipation per Rome IV criteria—were randomly allocated to the test and control groups. For 4 weeks, all were orally administered 5 daily drops of the test (L. reuteri DSM 17938 at 10(8) colony-forming units per day) or control (placebo) treatment, respectively. Participants were clinically assessed at 4 and 8 weeks. Parents were asked to daily record the number of spontaneous bowel movements (SBMs), stool consistency, and the use of any additional laxatives. Informed consent was obtained from parents of all recruited patients, and the study was approved by both an ethics committee and the French National Agency for Medicines and Health Products Safety (ANSM). The study is registered on ClinicalTrials.gov (NCT03030664). RESULTS: The change in SBMs relative to baseline was greater in the control group at week 4 (control: 0.27 ± 0.5; test: 0.23 ± 0.5; P = 0.01) and in the test group at week 8 (control: 0.26 ± 0.4; test: 0.22 ± 0.5; P = 0.03). At week 4, the groups did not differ in number of responders (≥3 stools per week, with no non-retentive fecal incontinence), use of rescue medication, scoring of pain during defecation (Faces Pain Scale–Revised), or stool consistency (Bristol Stool Form Scale). CONCLUSION: This double-blind randomized controlled trial did not confirm the efficacy of L. reuteri for treatment of chronic functional constipation in young children.
format Online
Article
Text
id pubmed-9643683
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96436832022-11-15 Effect of L. reuteri on bowel movements in children aged 6 months to 4 years: A double-blind randomized controlled trial Jung, Camille Kalach, Nicolas Degas, Vanessa Jeridi, Yasmine Bertrand, Valérie Bellaiche, Marc Front Pediatr Pediatrics BACKGROUND: Chronic constipation is common in children and often requires prolonged laxative treatment. Preliminary studies suggest that the probiotic Limosilactobacillus reuteri (L. reuteri) may be useful in treating constipation in children, but these preliminary results need to be replicated. The objective of this study was to assess the efficacy of L. reuteri in infants and young children with chronic functional constipation. METHODS: A prospective double-blind randomized placebo-controlled trial was conducted in 5 pediatric departments in France between June 2017 and June 2021. In all, 49 patients—ages 6 months to 4 years, and suffering from chronic constipation per Rome IV criteria—were randomly allocated to the test and control groups. For 4 weeks, all were orally administered 5 daily drops of the test (L. reuteri DSM 17938 at 10(8) colony-forming units per day) or control (placebo) treatment, respectively. Participants were clinically assessed at 4 and 8 weeks. Parents were asked to daily record the number of spontaneous bowel movements (SBMs), stool consistency, and the use of any additional laxatives. Informed consent was obtained from parents of all recruited patients, and the study was approved by both an ethics committee and the French National Agency for Medicines and Health Products Safety (ANSM). The study is registered on ClinicalTrials.gov (NCT03030664). RESULTS: The change in SBMs relative to baseline was greater in the control group at week 4 (control: 0.27 ± 0.5; test: 0.23 ± 0.5; P = 0.01) and in the test group at week 8 (control: 0.26 ± 0.4; test: 0.22 ± 0.5; P = 0.03). At week 4, the groups did not differ in number of responders (≥3 stools per week, with no non-retentive fecal incontinence), use of rescue medication, scoring of pain during defecation (Faces Pain Scale–Revised), or stool consistency (Bristol Stool Form Scale). CONCLUSION: This double-blind randomized controlled trial did not confirm the efficacy of L. reuteri for treatment of chronic functional constipation in young children. Frontiers Media S.A. 2022-10-26 /pmc/articles/PMC9643683/ /pubmed/36389355 http://dx.doi.org/10.3389/fped.2022.997104 Text en © 2022 Jung, Kalach, Degas, Jeridi, Bertrand and Bellaiche. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pediatrics
Jung, Camille
Kalach, Nicolas
Degas, Vanessa
Jeridi, Yasmine
Bertrand, Valérie
Bellaiche, Marc
Effect of L. reuteri on bowel movements in children aged 6 months to 4 years: A double-blind randomized controlled trial
title Effect of L. reuteri on bowel movements in children aged 6 months to 4 years: A double-blind randomized controlled trial
title_full Effect of L. reuteri on bowel movements in children aged 6 months to 4 years: A double-blind randomized controlled trial
title_fullStr Effect of L. reuteri on bowel movements in children aged 6 months to 4 years: A double-blind randomized controlled trial
title_full_unstemmed Effect of L. reuteri on bowel movements in children aged 6 months to 4 years: A double-blind randomized controlled trial
title_short Effect of L. reuteri on bowel movements in children aged 6 months to 4 years: A double-blind randomized controlled trial
title_sort effect of l. reuteri on bowel movements in children aged 6 months to 4 years: a double-blind randomized controlled trial
topic Pediatrics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643683/
https://www.ncbi.nlm.nih.gov/pubmed/36389355
http://dx.doi.org/10.3389/fped.2022.997104
work_keys_str_mv AT jungcamille effectoflreuterionbowelmovementsinchildrenaged6monthsto4yearsadoubleblindrandomizedcontrolledtrial
AT kalachnicolas effectoflreuterionbowelmovementsinchildrenaged6monthsto4yearsadoubleblindrandomizedcontrolledtrial
AT degasvanessa effectoflreuterionbowelmovementsinchildrenaged6monthsto4yearsadoubleblindrandomizedcontrolledtrial
AT jeridiyasmine effectoflreuterionbowelmovementsinchildrenaged6monthsto4yearsadoubleblindrandomizedcontrolledtrial
AT bertrandvalerie effectoflreuterionbowelmovementsinchildrenaged6monthsto4yearsadoubleblindrandomizedcontrolledtrial
AT bellaichemarc effectoflreuterionbowelmovementsinchildrenaged6monthsto4yearsadoubleblindrandomizedcontrolledtrial